# Mechanism of Ocrelizumab in B-Cell Depletion ## How does ocrelizumab target CD20-positive B cells to drive B-cell depletion? Ocrelizumab binds to CD20 on B cells and drives their depletion primarily through antibody-dependent cellular cytotoxicity mediated by monocytes via Fcγ receptor pathways, achieving rapid and sustained reduction of circulating B cells while also depleting CD20-positive T-cell subsets. ## Abstract Ocrelizumab is a humanized anti-CD20 monoclonal antibody that targets the same CD20 epitope as rituximab but achieves B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) rather than complement-dependent cytotoxicity (CDC). The antibody was engineered with amino acid modifications to enhance binding to Fcγ receptor IIIa, resulting in two- to five-fold greater ADCC activity compared to rituximab. Monocytes serve as the dominant effector cells mediating B-cell depletion through FcγRI and FcγRIII-dependent pathways, achieving rapid onset within hours and near-complete depletion (>95%) of circulating B cells by week 2. However, depletion efficiency varies across anatomical compartments, with secondary lymphoid organs retaining resistant B-cell subpopulations and bone marrow showing the weakest reduction. Ocrelizumab also co-depletes CD20-positive T-cell subsets and novel dual-expressor lymphocytes expressing both T-cell and B-cell receptors. B-cell recovery begins in bone marrow and spleen before appearing in blood, with median time to repletion of 72 weeks. The phenotype of reconstituting B cells varies by immunological context: in settings with ongoing antigen stimulation, recovery is characterized by expansion of differentiated, myelin-reactive B cells, whereas absence of stimulation favors naive B-cell reconstitution. Treatment induces secondary immunological changes including increased BAFF levels and decreased sTACI, which may enhance regulatory plasma cell development and contribute to therapeutic efficacy. The ADCC-predominant mechanism provides more sustained depletion than CDC-predominant antibodies while potentially offering better tolerability. ## Methods We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. More on methods Records from Elicit search n = 200 Papers screened using: Mechanistic Focus on CD20/B-cells, Specific Depletion Mechanisms, Study Type and Mechanistic Data, Mechanistic Content Present, CD20/B-cell Relevance, Study Rigor and Detail n = 200 Papers screened out n = 190 Papers included for extraction n = 10 ## Paper search We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex. We ran this query: “How does ocrelizumab target CD20-positive B cells to drive B-cell depletion?” The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening. ## Screening We screened in sources based on their abstracts that met these criteria: - **Mechanistic Focus on CD20/B-cells**: Does this study investigate ocrelizumab’s mechanism of action on CD20-positive B cells or B-cell depletion mechanisms induced by ocrelizumab? - **Specific Depletion Mechanisms**: Does this study examine specific mechanisms of B-cell depletion including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), apoptosis, CD20 binding affinity, epitope recognition, or receptor occupancy by ocrelizumab? - **Study Type and Mechanistic Data**: Is this an in vitro, in vivo (animal model), human study, systematic review, or meta-analysis that provides mechanistic data about ocrelizumab? - **Mechanistic Content Present**: Does this study provide mechanistic data beyond solely clinical efficacy or safety outcomes? - **CD20/B-cell Relevance**: If this study investigates ocrelizumab effects on non-B cell populations, does it include reference to CD20 or B-cell depletion mechanisms? - **Study Rigor and Detail**: Is this study something other than a case report, case series, conference abstract, or preliminary report lacking sufficient mechanistic investigation or methodological detail? We considered all screening questions together and made a holistic judgement about whether to screen in each paper. ## Data extraction We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column. ### CD20 Targeting - CD20 epitope specificity and binding characteristics - Binding affinity (Kd values, if reported) - Antibody structure features that affect CD20 binding (humanization level, glycosylation, Fc region modifications) - Any comparison of binding characteristics to other anti-CD20 antibodies (rituximab, ofatumumab, ublituximab) - Dose-response relationships for CD20 binding ### Cytotoxic Mechanisms - Complement-dependent cytotoxicity (CDC) activity and potency - Antibody-dependent cellular cytotoxicity (ADCC) activity and potency - Direct apoptosis induction - Other cytotoxic pathways (if mentioned) - Quantitative comparisons of mechanism potency (e.g., EC50 values, percentage lysis) - Time course of cytotoxicity for each mechanism - Any genetic or phenotypic factors that affect cytotoxic efficacy ### Depletion Patterns - Specific B-cell subpopulations targeted (naive, memory, plasma cells, transitional B cells) - B-cell populations that are resistant to depletion - Anatomical compartments affected (blood, bone marrow, spleen, lymph nodes, CNS/brain) - Degree of depletion in each compartment (percentage reduction, absolute counts) - Any co-depletion of CD20+ T cells or other immune cells - Factors that influence depletion efficiency (dose, patient characteristics, genetic polymorphisms) ### Depletion Kinetics - Time to initial B-cell depletion (onset) - Duration of maximal depletion - Recovery timeline for different B-cell populations - Recovery timeline for different anatomical compartments - Sequence of B-cell reconstitution (which populations recover first) - Phenotype of reconstituting B-cells (naive vs memory characteristics) - Any differences in recovery kinetics compared to other anti-CD20 antibodies ### Molecular Determinants - Antibody type (humanized, chimeric, fully human) - Heavy and light chain sequences (if provided) - Fc region modifications or glycoengineering - Pharmacokinetic properties affecting mechanism (half-life, tissue distribution) - Dosing regimen and how it relates to mechanism optimization - Route of administration (IV vs subcutaneous) and mechanistic implications - Any engineering specifically designed to enhance B-cell depletion ### Comparative Mechanisms - Head-to-head mechanistic comparisons with rituximab, ofatumumab, ublituximab, or other anti-CD20 agents - Relative potency differences in CDC vs ADCC mechanisms - Differences in B-cell depletion patterns between antibodies - Differences in depletion kinetics between antibodies - Unique mechanistic features of ocrelizumab vs competitors - Clinical implications of mechanistic differences (efficacy, safety, dosing requirements) ## Results ### Characteristics of Included Studies | Study | Full text retrieved? | Study focus | Key features | |-------------------------------------|---------------------|--------------------------------------------|---------------| | J. Uchida et al., 2004 | Yes | Mouse model of anti-CD20 therapy | Developed mouse anti-mouse CD20 antibody panel to study B-cell depletion mechanisms | | B. Cree et al., 2025 | Yes | Review of anti-CD20 antibody evolution | Comprehensive comparison of ocrelizumab, ofatumumab, ublituximab, and rituximab | | Pacheco-Fernández et al., 2018 | No | In vitro CDC comparison | Compared ofatumumab and ocrelizumab CDC activity using B-cell lines | | Samantha Ho et al., 2023 | Yes | B-cell regulating factors | Examined effects on BAFF-APRIL system over 2.5 years | | Schneider-Hohendorf et al., 2025 | No | B- and T-cell receptor repertoires | Analyzed adaptive immune changes in 35 MS patients on ocrelizumab | | Alice Willison et al., 2025 | Yes | Immune cell dynamics comparison | Compared ocrelizumab (n=34) and ofatumumab (n=25) with flow cytometry | | A. Bar-Or et al., 2021 | Yes | Clinical perspectives review | Detailed molecular and pharmacological attributes of four anti-CD20 antibodies | | Darius Häusler et al., 2018 | Yes | EAE model of B-cell recovery | Characterized B-cell depletion and reconstitution in murine MS model | | S. A. Kornilov et al., 2024 | No | Multi-omic characterization | Analyzed plasma proteome, metabolome, and lipidome changes in 14 RRMS patients | | Prajita Paul et al., 2025 | No | Dual-expressor lymphocytes | Identified novel TCR/IgM dual-expressor cells susceptible to anti-CD20 therapy | The studies employed diverse methodological approaches, including murine models, in vitro cell line assays, human longitudinal cohort studies, and comprehensive reviews. Full-text availability varied, with six studies providing complete manuscripts and four available only as abstracts. Study populations ranged from mouse models to human RRMS cohorts, with sample sizes for human studies ranging from 14 to 35 patients. ## Mechanisms of CD20 Targeting and B-cell Depletion ### CD20 Binding Characteristics Ocrelizumab is a humanized anti-CD20 monoclonal antibody that binds to the same epitope on the large extracellular loop of CD20 as rituximab. The antibody is classified as a type I anti-CD20 agent capable of crosslinking CD20 tetramers. Enhanced binding to low-affinity variants of Fcγ receptor IIIa distinguishes ocrelizumab from rituximab, contributing to its enhanced effector function. The antibody was specifically engineered through amino acid modifications in its Fc region to increase antibody-dependent cellular cytotoxicity (ADCC) activity. ### Cytotoxic Mechanisms Ocrelizumab depletes B cells through multiple cytotoxic pathways, with ADCC as the primary mechanism. The antibody exhibits two- to five-fold greater ADCC activity compared to rituximab, while demonstrating three- to five-fold lower complement-dependent cytotoxicity (CDC) activity. Both ocrelizumab and ofatumumab can induce ADCC and CDC, though ofatumumab demonstrates stronger CDC effects, particularly at low CD20 expression levels. In vitro comparisons using human B-cell lines revealed that ocrelizumab induced less cell lysis through CDC compared to ofatumumab, with the strongest differentiation observed when complement was added 8 hours after antibody washing, showing the hierarchy: ofatumumab > rituximab > ocrelizumab. The dominance of ADCC over CDC in ocrelizumab’s mechanism of action has important implications. Studies in mouse models demonstrated that B-cell depletion is completely dependent on effector cell Fc receptor expression, with monocytes serving as the dominant effector cells. The depletion pathway utilizes both FcγRI and FcγRIII-dependent mechanisms, while genetic deficiency in complement components (C3, C4, or C1q) did not prevent B-cell elimination, confirming the primacy of ADCC over CDC in vivo. ## Patterns of B-cell Depletion ### B-cell Subpopulations Ocrelizumab targets CD20-positive B cells, resulting in significant reductions across multiple B-cell subsets including naive B cells, memory B cells, transitional B cells, and plasmablasts. Plasma cells, which lack CD20 expression, remain resistant to depletion, as do CD20-negative B-cell precursors and hematopoietic stem cells. An expansion of CD5+CD19+CD20− B cells was observed following treatment, indicating a population resistant to depletion. Circulating B-cell counts showed almost complete depletion by week 2, remaining depleted through week 96 with infusions every 24 weeks. ### Non-B-cell Targets Beyond conventional B cells, ocrelizumab co-depletes CD20-positive T-cell subsets. Significant reductions occurred in double-negative (CD3+CD4−CD8−) T cells, which express higher CD20 levels compared to CD4 or CD8 positive T cells. Depletion was evident in highly expanded T-cell receptor beta chain and Vδ2+ T-cell receptor delta chain clonotypes. The treatment also targets novel dual-expressor cells (DEs) that co-express T-cell receptors and surface IgM, with up to 95% of DEs in cerebrospinal fluid expressing CD20. These DEs were found at significantly higher frequencies in RRMS patients compared to healthy controls and showed robust responses to myelin autoantigens. ### Anatomical Compartments B-cell depletion occurs across multiple anatomical compartments but with varying efficiency. In blood, depletion is nearly complete, with more than 95% reduction in circulating B cells. However, B cells in lymphatic organs and the CNS are not depleted to the same extent as those in blood. Secondary lymphoid organs including the spleen and lymph nodes retain a subpopulation of CD20-positive B cells resistant to depletion, with splenic B cells showing more than 93% reduction. The bone marrow demonstrates the weakest reduction in B-cell numbers, with persistence of CD20-negative B-cell precursors and plasma cells. CSF B cells are substantially reduced following treatment, with tissue-resident memory cells in cerebrospinal fluid showing initial therapy resistance. ## Kinetics of Depletion and Recovery ### Depletion Timeline The onset of B-cell depletion is rapid, occurring within 1 hour in mouse models, with CD19+ cell counts in humans almost completely depleted by week 2 after the first dose. Maximal depletion persists for extended periods, with B cells remaining extensively depleted through week 96 when infusions are administered every 24 weeks. In longitudinal human studies, persistent depletion of B cells and CD20+ T cells was observed for up to 2.5 years. Depletion at 6 months was associated with reduction in B-cell associated proteins. ### Recovery Patterns B-cell recovery demonstrates complex kinetics varying by anatomical compartment and B-cell phenotype. In mouse models, bone marrow and spleen show simultaneous recovery, with B cells reappearing at 6 weeks and fully restored by 9 weeks, substantially preceding reappearance in blood. Lymph nodes and blood recover more slowly, with full repletion not achieved until 12 weeks. In humans, B-cell levels increase to baseline or the lower limit of normal in 90% of patients within 2.5 years after the last infusion, with a median time to repletion of 72 weeks. The phenotype of reconstituting B cells depends on disease context. In experimental autoimmune encephalomyelitis (EAE) models involving activated B cells (MOG protein 1-117), recovery was characterized by expansion of mature, differentiated cells containing high frequencies of myelin-reactive B cells with restricted B-cell receptor gene diversity. These cells served as efficient antigen-presenting cells for myelin-specific T-cell activation. In contrast, in purely T-cell-mediated EAE models (MOG peptide 35-55), reconstituting B cells exhibited a naive phenotype without efficient antigen-presenting capacity. Human studies showed a bimodal distribution six months after initial depletion: some patients had few B cells with high somatic hypermutation consistent with incomplete depletion of differentiated B cells, while others had higher numbers of less differentiated B cells indicating reconstitution from germline. Extended interval dosing was associated with higher percentages of naive, transitional, and regulatory B cells, suggesting these populations recover first. Fast B-cell repopulation starting around 6 months was associated with higher MRI activity and worsening disability, indicating clinical relevance of recovery kinetics. Studies showed that 26% of patients had B-cell repletion at 6 months. ## Comparative Analysis with Other Anti-CD20 Antibodies ### Mechanistic Distinctions Ocrelizumab exhibits distinct mechanistic properties compared to other anti-CD20 antibodies. While all anti-CD20 agents induce both ADCC and CDC, their relative reliance on these pathways differs substantially. Ocrelizumab and ublituximab primarily use ADCC for B-cell depletion, whereas rituximab and ofatumumab rely more heavily on CDC. Ofatumumab demonstrates greater CDC potency compared to ocrelizumab, which may explain its efficacy at lower doses. Ublituximab shows more pronounced ADCC effects than rituximab, ocrelizumab, and ofatumumab due to its glycoengineered Fc segment. The enhanced ADCC activity of ocrelizumab, achieved through amino acid engineering to increase binding to Fcγ receptor IIIa, is two- to five-fold greater than rituximab, while its CDC activity is three- to five-fold lower. This mechanistic profile has important clinical implications, as ADCC-mediated depletion is associated with fewer infusion-related reactions compared to CDC-mediated pathways. ### Depletion Efficiency and Clinical Impact Ocrelizumab achieves more complete and sustained B-cell depletion compared to rituximab. The extent of B-cell depletion may affect clinical efficacy, with higher median B-cell levels potentially associated with higher rates of disability progression. Ocrelizumab shows slower B-cell repletion rates compared to ofatumumab, which may contribute to differences in dosing requirements. The antibody is administered intravenously at 300 mg initially, followed by 300 mg two weeks later, then 600 mg every 6 months, compared to ofatumumab’s low-dose subcutaneous regimen enabled by its stronger CDC activity. ## Secondary Effects on Immune Regulation ### BAFF-APRIL System Modulation Ocrelizumab treatment induces profound changes in the B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) system. The treatment persistently enhances BAFF levels while reducing the endogenous soluble receptor and decoy sTACI in both serum and CSF. Levels of sTACI negatively correlate with BAFF levels, with reduction of sTACI associated with formation of sTACI-BAFF complexes. The pronounced increase in circulating BAFF following CD20 depletion represents a tentative compensatory mechanism that may contribute to reconstitution of targeted B cells. Since sTACI is a decoy for APRIL, its reduction may enhance local APRIL activity, thereby promoting regulatory IgA+ plasma cells and astrocytic IL-10 production. This mechanism may contribute to the beneficial effects of anti-CD20 therapy, as exogenous sTACI (atacicept) worsened MS. The therapeutic effects of ocrelizumab extend beyond CD20-mediated B-cell lysis to implicate metabolic reprogramming. ### Broader Immunological Changes B-cell depletion is accompanied by decreases in B-cell receptor and cytokine signaling pathways. At 6 months, treatment reduces plasma abundance of cytokines and cytotoxic proteins, markers of neuronal damage, and biologically active lipids including ceramides and lysophospholipids. This is followed by upregulation of numerous signaling and metabolic pathways at 12 months. Ocrelizumab treatment also elevates exhaustion markers (CTLA-4, PD-1, TIGIT, TIM-3) across T, B, NK, and NKT cells. Regulatory T-cell numbers increase, especially in ocrelizumab-treated patients. Digital cytometry identified a putative increase in myeloid cells and a pro-inflammatory subset of T cells. These immune profile changes correlate with clinical parameters, suggesting pathophysiological relevance in RRMS. ## Synthesis The mechanism by which ocrelizumab drives B-cell depletion involves multiple coordinated processes that vary by context, anatomical location, and B-cell phenotype. The apparent heterogeneity in depletion efficiency and recovery patterns across different compartments and studies can be reconciled through several key considerations. ### Mechanistic Heterogeneity by Anatomical Context The differential depletion efficiency across anatomical compartments reflects distinct microenvironmental factors rather than conflicting findings. Blood shows near-complete depletion (>95%), whereas secondary lymphoid organs retain resistant subpopulations and bone marrow shows the weakest reduction. This pattern is mechanistically consistent with the ADCC-dependent mechanism of ocrelizumab. Blood provides optimal access for effector monocytes, while follicular B cells in lymphoid tissues may be protected by anatomical barriers or local factors that limit monocyte access. The persistence of plasma cells across all compartments reflects their lack of CD20 expression rather than resistance to the antibody’s cytotoxic mechanism. ### Recovery Phenotype Determined by Disease Activity The divergent phenotypes of reconstituting B cells—ranging from highly mutated memory-like cells to naive populations—reflect the immunological context at recovery rather than inconsistent biology. In models where B cells are actively engaged in antigen presentation (MOG protein 1-117 EAE), recovery populations are enriched for mature, myelin-reactive cells with efficient APC capacity. In purely T-cell-mediated models (MOG peptide 35-55 EAE), naive phenotypes predominate. This suggests that ongoing antigenic stimulation during the recovery phase selectively expands differentiated B-cell clones that survive in lymphoid tissues, while absence of such stimulation favors reconstitution from naive precursors. The bimodal distribution in human patients at 6 months—with some showing few highly mutated cells and others showing numerous less differentiated cells—likely represents these two extremes occurring within a single patient population. Patients with incomplete depletion of tissue-resident differentiated B cells will show the first pattern, while those with more complete depletion will demonstrate the second. The association of fast repopulation with worse clinical outcomes supports the pathogenic relevance of early-recovering differentiated populations. ### ADCC vs CDC Balance and Clinical Optimization The comparative studies showing stronger CDC activity for ofatumumab versus ocrelizumab do not indicate superior efficacy, but rather different optimization strategies. Ofatumumab’s potent CDC enables low-dose subcutaneous administration, while ocrelizumab’s enhanced ADCC (2-5 fold greater than rituximab) allows for less frequent dosing and potentially better tolerability, as ADCC generates fewer infusion-related reactions than CDC. Both mechanisms achieve effective B-cell depletion; the choice reflects different balancing of efficacy, safety, and convenience. ### Compensatory Mechanisms and Long-term Effects The increase in BAFF following B-cell depletion represents a predictable homeostatic response rather than a treatment failure. The simultaneous decrease in sTACI may actually enhance therapeutic benefit by allowing more free APRIL to promote regulatory plasma cells and IL-10 production. This explains the apparent paradox where exogenous sTACI (atacicept) worsened MS, despite its theoretical B-cell depleting effects. The therapeutic window for anti-CD20 therapy thus involves balancing B-cell depletion against preservation of regulatory mechanisms, with the BAFF-APRIL system serving as a key mediator of this balance. ## References 1. [J. Uchida et al., 2004. The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy. Journal of Experimental Medicine](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-1219552/index.html) 2. [B. Cree et al., 2025. The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function. CNS Drugs](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-277547534/index.html) 3. [Thalia Pacheco-Fernández et al., 2018. Anti-CD20 Antibodies Ofatumumab and Ocrelizumab Have Distinct Effects on Human B-cell Survival (S52.003). Neurology](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-81368773/index.html) 4. [Samantha Ho et al., 2023. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis. Neurology: Neuroimmunology & Neuroinflammation](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-256303612/index.html) 5. [T. Schneider-Hohendorf et al., 2025. B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab. iScience](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-280106681/index.html) 6. [Alice Willison et al., 2025. Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis. Cells](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-277674619/index.html) 7. [A. Bar-Or et al., 2021. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. CNS Drugs](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-236958170/index.html) 8. [Darius Häusler et al., 2018. Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-52172874/index.html) 9. [S. A. Kornilov et al., 2024. Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis. Journal of Neurological Sciences](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-273959805/index.html) 10. [Prajita Paul et al., 2025. Myelin-Reactive TCR/IgM Dual-Expresser Lymphocytes in Multiple Sclerosis: Linking Pathogenesis to Anti-CD20 Therapy. Immunological Investigations](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-281329396/index.html)